大葉大學圖書館 |

Clinical trials of antidepressants[electronic resource] :how changing the model can uncover new, more effective molecules /

Record Type:	Language materials, printed : Monograph/item
[NT 15000414]:	610.727
Title/Author:	Clinical trials of antidepressants : how changing the model can uncover new, more effective molecules // by Martin M. Katz.
Author:	Katz, Martin M.
Published:	Cham : : Springer International Publishing :, 2016.
Description:	xv, 66 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
Subject:	Clinical trials - Statistical methods.
Subject:	Clinical trials - Mathematical models.
Subject:	Antidepressants - Evaluation.
Subject:	Psychology.
Subject:	Health Psychology.
ISBN:	9783319264646
ISBN:	9783319264639
[NT 15000228]:	Introduction -- Why Now the Need for a New Clinical Trial Model for Antidepressants? -- Reconceptualizing Depression and the Componential-Specific Model of Clinical Trials -- Aims and Basic requirements of Clinical Trials: Conventional and Component-Specific Models -- Methods for Measuring the Components and Profile of Drug Actions: The Multivantaged Approach -- The Component-Specific Model Applied in a Clinical Trial: An Example -- Comparing the Component-Specific Model Directly with the Established Diagnosis-Specific Trial -- Prediction and Shortening the Clinical Trial: Further Advantages of the Component-Specific Model -- The Video Clinical Trial and the VIBES Method -- Conclusions.
[NT 15000229]:	This brief guide takes current clinical trial protocols to task and replaces them with a contemporary framework for improving next-generation antidepressants and their underlying science. Innovative models are based on a nuanced, neurologically-informed understanding of drug mechanisms and the component cognitive, mood, and behavioral aspects of depression. The book reconceptualizes not only the clinical trial process but the clinical concept of depression itself as essential to bringing pharmaceutical research and development up to date, boosting efficiency and effectiveness, finding new molecules, and reducing waste. Case studies and a review of salient depression scales illustrate the potential benefits of such wide-scale change. Included in the coverage: Why now the need for a new clinical trials model for antidepressants? Aims and basic requirements of clinical trials: conventional and component-specific models. Methods for measuring the components and the profile of drug actions: the multivantaged approach. Achieving the ideal clinical trial: an example of the merged componential and established models. Prediction and shortening the clinical trial. The video clinical trial. Clinical Trials of Antidepressants will interest a varied audience, including clinical investigators, academic and pharmaceutical company scientists, clinical trial organizations, psychiatrists, outpatient physicians, psychotherapists, clinical psychologists, psychology graduate students, medical students, and government agencies such as the FDA.
Online resource:	http://dx.doi.org/10.1007/978-3-319-26464-6

Clinical trials of antidepressants[electronic resource] :how changing the model can uncover new, more effective molecules /
Katz, Martin M.

Clinical trials of antidepressantshow changing the model can uncover new, more effective molecules /[electronic resource] :by Martin M. Katz. - Cham :Springer International Publishing :2016. - xv, 66 p. :ill., digital ;24 cm. - SpringerBriefs in psychology,2192-8363. - SpringerBriefs in psychology..

Introduction -- Why Now the Need for a New Clinical Trial Model for Antidepressants? -- Reconceptualizing Depression and the Componential-Specific Model of Clinical Trials -- Aims and Basic requirements of Clinical Trials: Conventional and Component-Specific Models -- Methods for Measuring the Components and Profile of Drug Actions: The Multivantaged Approach -- The Component-Specific Model Applied in a Clinical Trial: An Example -- Comparing the Component-Specific Model Directly with the Established Diagnosis-Specific Trial -- Prediction and Shortening the Clinical Trial: Further Advantages of the Component-Specific Model -- The Video Clinical Trial and the VIBES Method -- Conclusions.

This brief guide takes current clinical trial protocols to task and replaces them with a contemporary framework for improving next-generation antidepressants and their underlying science. Innovative models are based on a nuanced, neurologically-informed understanding of drug mechanisms and the component cognitive, mood, and behavioral aspects of depression. The book reconceptualizes not only the clinical trial process but the clinical concept of depression itself as essential to bringing pharmaceutical research and development up to date, boosting efficiency and effectiveness, finding new molecules, and reducing waste. Case studies and a review of salient depression scales illustrate the potential benefits of such wide-scale change. Included in the coverage: Why now the need for a new clinical trials model for antidepressants? Aims and basic requirements of clinical trials: conventional and component-specific models. Methods for measuring the components and the profile of drug actions: the multivantaged approach. Achieving the ideal clinical trial: an example of the merged componential and established models. Prediction and shortening the clinical trial. The video clinical trial. Clinical Trials of Antidepressants will interest a varied audience, including clinical investigators, academic and pharmaceutical company scientists, clinical trial organizations, psychiatrists, outpatient physicians, psychotherapists, clinical psychologists, psychology graduate students, medical students, and government agencies such as the FDA.

ISBN: 9783319264646

Standard No.: 10.1007/978-3-319-26464-6doiSubjects--Topical Terms:

467884
Clinical trials
--Statistical methods.

LC Class. No.: R853.S7

Dewey Class. No.: 610.727

Clinical trials of antidepressants[electronic resource] :how changing the model can uncover new, more effective molecules /
LDR:03323nam a2200337 a 4500 001 456442
003 DE-He213
005 20160823101705.0
006 m d
007 cr nn 008maaau
008 161227s2016 gw s 0 eng d
020 $a 9783319264646 $q (electronic bk.)
020 $a 9783319264639 $q (paper)
024 7 $a 10.1007/978-3-319-26464-6 $2 doi
035 $a 978-3-319-26464-6
040 $a GP $c GP
041 0 $a eng
050 4 $a R853.S7
072 7 $a MBNH9 $2 bicssc
072 7 $a PSY003000 $2 bisacsh
072 7 $a MED078000 $2 bisacsh
082 0 4 $a 610.727 $2 23
090 $a R853.S7 $b K19 2016
100 1 $a Katz, Martin M. $3 655827
245 1 0 $a Clinical trials of antidepressants $h [electronic resource] : $b how changing the model can uncover new, more effective molecules / $c by Martin M. Katz.
260 $a Cham : $c 2016. $b Springer International Publishing : $b Imprint: Springer,
300 $a xv, 66 p. : $b ill., digital ; $c 24 cm.
490 1 $a SpringerBriefs in psychology, $x 2192-8363
505 0 $a Introduction -- Why Now the Need for a New Clinical Trial Model for Antidepressants? -- Reconceptualizing Depression and the Componential-Specific Model of Clinical Trials -- Aims and Basic requirements of Clinical Trials: Conventional and Component-Specific Models -- Methods for Measuring the Components and Profile of Drug Actions: The Multivantaged Approach -- The Component-Specific Model Applied in a Clinical Trial: An Example -- Comparing the Component-Specific Model Directly with the Established Diagnosis-Specific Trial -- Prediction and Shortening the Clinical Trial: Further Advantages of the Component-Specific Model -- The Video Clinical Trial and the VIBES Method -- Conclusions.
520 $a This brief guide takes current clinical trial protocols to task and replaces them with a contemporary framework for improving next-generation antidepressants and their underlying science. Innovative models are based on a nuanced, neurologically-informed understanding of drug mechanisms and the component cognitive, mood, and behavioral aspects of depression. The book reconceptualizes not only the clinical trial process but the clinical concept of depression itself as essential to bringing pharmaceutical research and development up to date, boosting efficiency and effectiveness, finding new molecules, and reducing waste. Case studies and a review of salient depression scales illustrate the potential benefits of such wide-scale change. Included in the coverage: Why now the need for a new clinical trials model for antidepressants? Aims and basic requirements of clinical trials: conventional and component-specific models. Methods for measuring the components and the profile of drug actions: the multivantaged approach. Achieving the ideal clinical trial: an example of the merged componential and established models. Prediction and shortening the clinical trial. The video clinical trial. Clinical Trials of Antidepressants will interest a varied audience, including clinical investigators, academic and pharmaceutical company scientists, clinical trial organizations, psychiatrists, outpatient physicians, psychotherapists, clinical psychologists, psychology graduate students, medical students, and government agencies such as the FDA.
650 0 $a Clinical trials $x Statistical methods. $3 467884
650 0 $a Clinical trials $x Mathematical models. $3 655828
650 0 $a Antidepressants $x Evaluation. $3 655829
650 1 4 $a Psychology. $3 180630
650 2 4 $a Health Psychology. $3 463506
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a SpringerBriefs in psychology. $3 468664
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-26464-6
950 $a Behavioral Science and Psychology (Springer-41168)